Advertisement
UK markets close in 2 hours 23 minutes

  • FTSE 100

    8,067.49
    +27.11 (+0.34%)
     

  • FTSE 250

    19,661.05
    -58.32 (-0.30%)
     

  • AIM

    754.52
    -0.17 (-0.02%)
     

  • GBP/EUR

    1.1668
    +0.0023 (+0.20%)
     

  • GBP/USD

    1.2474
    +0.0012 (+0.10%)
     

  • Bitcoin GBP

    50,675.73
    -2,351.32 (-4.43%)
     

  • CMC Crypto 200

    1,353.74
    -28.83 (-2.08%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.85
    +0.04 (+0.05%)
     

  • GOLD FUTURES

    2,343.60
    +5.20 (+0.22%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,913.33
    -175.37 (-0.97%)
     

  • CAC 40

    7,987.16
    -104.70 (-1.29%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference

Merus N.V.
·1-min read
Merus N.V.
Merus N.V.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10 at 12:45 p.m. ET.

The webcast of the fireside chat will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

ADVERTISEMENT
CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. VP Investor Relations and Corporate Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl